X0306 4 2020-12-02 1 0000875622 BIOSPECIFICS TECHNOLOGIES CORP BSTC 0001452429 Truitt Joseph C/O BIOSPECIFICS TECHNOLOGIES CORP. 2 RIGHTER PKWY, DE CORP CENTER II WILMINGTON DE 19803 1 1 0 0 Chief Executive Officer Stock Option (Right to Buy) 63.72 2020-12-02 4 D 0 100000 24.78 D 2030-05-28 Common Stock 100000 0 D Upon the consummation of the merger contemplated by that certain Agreement and Plan of Merger, by and among BioSpecifics Technologies Corp., Endo International plc, and Beta Acquisition Corp., dated October 19, 2020, the stock options, which provided for vesting in four equal annual installments following the grant date (May 28, 2020), were canceled in exchange for a cash payment of $2,478,000.00, representing the product obtained by multiplying (x) the aggregate number of shares of common stock underlying the stock options by (y) the amount by which the offer price ($88.50) exceeds the per share exercise price of such stock option. /s/ Joseph E. Truitt by Carl A. Valenstein, attorney- in-fact 2020-12-02